Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gogo Inc. stock logo
GOGO
Gogo
$4.57
-4.4%
$4.33
$3.81
$16.82
$618.05M1.061.87 million shs2.45 million shs
Kohl's Corporation stock logo
KSS
Kohl's
$14.41
-7.6%
$13.42
$7.82
$25.22
$1.62B1.464.72 million shs9.95 million shs
Kohl's Corporation stock logo
KSS
Kohl's
$14.41
-7.6%
$13.42
$7.82
$25.22
$1.62B1.464.72 million shs9.95 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,105.37
-1.9%
$952.15
$623.78
$1,149.10
$1.04T0.483.21 million shs4.57 million shs
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
$14.07
+2.9%
$13.53
$6.83
$28.25
$1.97B1.935.50 million shs5.53 million shs
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
$11.13
$11.13
$3.89
$11.41
$992.13M2.234.91 million shsN/A
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gogo Inc. stock logo
GOGO
Gogo
+1.70%+19.50%+18.32%+13.00%-55.82%
Kohl's Corporation stock logo
KSS
Kohl's
+20.14%+22.83%+5.53%-4.45%+91.47%
Kohl's Corporation stock logo
KSS
Kohl's
+20.14%+22.83%+5.53%-4.45%+91.47%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+3.81%+8.14%+28.89%+7.26%+56.79%
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
+1.79%+10.59%+3.64%-0.73%+41.61%
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
0.00%0.00%0.00%0.00%+162.50%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gogo Inc. stock logo
GOGO
Gogo
$4.57
-4.4%
$4.33
$3.81
$16.82
$618.05M1.061.87 million shs2.45 million shs
Kohl's Corporation stock logo
KSS
Kohl's
$14.41
-7.6%
$13.42
$7.82
$25.22
$1.62B1.464.72 million shs9.95 million shs
Kohl's Corporation stock logo
KSS
Kohl's
$14.41
-7.6%
$13.42
$7.82
$25.22
$1.62B1.464.72 million shs9.95 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,105.37
-1.9%
$952.15
$623.78
$1,149.10
$1.04T0.483.21 million shs4.57 million shs
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
$14.07
+2.9%
$13.53
$6.83
$28.25
$1.97B1.935.50 million shs5.53 million shs
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
$11.13
$11.13
$3.89
$11.41
$992.13M2.234.91 million shsN/A
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gogo Inc. stock logo
GOGO
Gogo
+1.70%+19.50%+18.32%+13.00%-55.82%
Kohl's Corporation stock logo
KSS
Kohl's
+20.14%+22.83%+5.53%-4.45%+91.47%
Kohl's Corporation stock logo
KSS
Kohl's
+20.14%+22.83%+5.53%-4.45%+91.47%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+3.81%+8.14%+28.89%+7.26%+56.79%
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
+1.79%+10.59%+3.64%-0.73%+41.61%
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
0.00%0.00%0.00%0.00%+162.50%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Gogo Inc. stock logo
GOGO
Gogo
2.00
Hold$9.50107.88% Upside
Kohl's Corporation stock logo
KSS
Kohl's
1.75
Reduce$14.772.51% Upside
Kohl's Corporation stock logo
KSS
Kohl's
1.75
Reduce$14.772.51% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.87
Moderate Buy$1,227.0011.00% Upside
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
2.35
Hold$20.2543.92% Upside
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
2.00
Hold$12.6013.21% Upside

Current Analyst Ratings Breakdown

Latest KSS, NTLA, GOGO, LLY, VERV, and KSS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/29/2026
Kohl's Corporation stock logo
KSS
Kohl's
Lower Price TargetUnderperform$15.00 ➝ $14.00
5/29/2026
Kohl's Corporation stock logo
KSS
Kohl's
Lower Price TargetUnderperform$15.00 ➝ $14.00
5/29/2026
Kohl's Corporation stock logo
KSS
Kohl's
Lower Price Target$15.00 ➝ $14.00
5/29/2026
Kohl's Corporation stock logo
KSS
Kohl's
Boost Price TargetSell$8.00 ➝ $9.00
5/29/2026
Kohl's Corporation stock logo
KSS
Kohl's
Lower Price Target$15.00 ➝ $14.00
5/29/2026
Kohl's Corporation stock logo
KSS
Kohl's
Boost Price TargetSell$8.00 ➝ $9.00
5/26/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,133.00 ➝ $1,251.00
5/26/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Set Price Target$1,119.00
5/22/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingBuy$1,283.00
5/21/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOutperform$1,350.00
5/21/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOutperform
(Data available from 5/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Gogo Inc. stock logo
GOGO
Gogo
$910.49M0.68$0.81 per share5.63$0.87 per share5.25
Kohl's Corporation stock logo
KSS
Kohl's
$15.53B0.10$8.79 per share1.64$36.08 per share0.40
Kohl's Corporation stock logo
KSS
Kohl's
$15.53B0.10$8.79 per share1.64$36.08 per share0.40
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B15.97$25.66 per share43.08$33.13 per share33.36
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
$67.67M29.05N/AN/A$4.44 per share3.17
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
$32.33M30.69N/AN/A$5.83 per share1.91
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Gogo Inc. stock logo
GOGO
Gogo
$12.92M$0.1141.558.46N/A1.54%37.53%3.13%8/6/2026 (Estimated)
Kohl's Corporation stock logo
KSS
Kohl's
$272M$2.366.1110.22N/A1.75%4.72%1.36%N/A
Kohl's Corporation stock logo
KSS
Kohl's
$272M$2.366.1110.22N/A1.75%4.72%1.36%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$28.1539.2724.941.1834.98%105.77%23.76%8/5/2026 (Estimated)
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
-$412.69M-$3.54N/AN/AN/A-597.04%-57.47%-46.24%8/6/2026 (Estimated)
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
-$198.71M-$2.11N/AN/AN/A-303.64%-35.81%-27.57%N/A

Latest KSS, NTLA, GOGO, LLY, VERV, and KSS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/28/2026Q1 2027
Kohl's Corporation stock logo
KSS
Kohl's
-$0.18-$0.13+$0.05-$0.13$2.99 billion$3.17 billion
5/28/2026Q1 2027
Kohl's Corporation stock logo
KSS
Kohl's
-$0.18-$0.13+$0.05-$0.13$2.99 billion$3.17 billion
5/11/2026Q1 2026
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
-$0.92-$0.81+$0.11-$0.81$13.81 million$15.05 million
4/30/2026Q1 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.97$8.55+$1.58$8.26$17.82 billion$19.80 billion
3/10/2026Q4 2026
Kohl's Corporation stock logo
KSS
Kohl's
$0.86$1.07+$0.21$1.07$5.08 billion$5.17 billion
3/10/2026Q4 2026
Kohl's Corporation stock logo
KSS
Kohl's
$0.86$1.07+$0.21$1.07$5.08 billion$5.17 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Gogo Inc. stock logo
GOGO
Gogo
N/AN/AN/AN/AN/A
Kohl's Corporation stock logo
KSS
Kohl's
$0.503.47%-6.51%21.19%N/A
Kohl's Corporation stock logo
KSS
Kohl's
$0.503.47%-6.51%21.19%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.63%+15.18%24.58%11 Years
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
N/AN/AN/AN/AN/A
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
N/AN/AN/AN/AN/A

Latest KSS, NTLA, GOGO, LLY, VERV, and KSS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/20/2026
Kohl's Corporation stock logo
KSS
Kohl's
quarterly$0.12504.09%6/10/20266/10/20266/24/2026
5/20/2026
Kohl's Corporation stock logo
KSS
Kohl's
quarterly$0.12504.09%6/10/20266/10/20266/24/2026
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.69%5/15/20265/15/20266/10/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Gogo Inc. stock logo
GOGO
Gogo
6.89
1.66
1.27
Kohl's Corporation stock logo
KSS
Kohl's
0.94
1.46
0.37
Kohl's Corporation stock logo
KSS
Kohl's
0.94
1.46
0.37
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.26
1.50
1.10
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
N/A
6.10
6.10
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
N/A
9.84
9.84

Institutional Ownership

CompanyInstitutional Ownership
Gogo Inc. stock logo
GOGO
Gogo
69.60%
Kohl's Corporation stock logo
KSS
Kohl's
98.04%
Kohl's Corporation stock logo
KSS
Kohl's
98.04%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
88.77%
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
97.11%

Insider Ownership

CompanyInsider Ownership
Gogo Inc. stock logo
GOGO
Gogo
25.60%
Kohl's Corporation stock logo
KSS
Kohl's
1.55%
Kohl's Corporation stock logo
KSS
Kohl's
1.55%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
3.10%
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
19.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Gogo Inc. stock logo
GOGO
Gogo
380135.24 million100.62 millionOptionable
Kohl's Corporation stock logo
KSS
Kohl's
84,000112.25 million110.51 millionOptionable
Kohl's Corporation stock logo
KSS
Kohl's
84,000112.25 million110.51 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000941.74 million940.42 millionOptionable
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
600139.72 million135.39 millionOptionable
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
11089.14 million71.94 millionOptionable

Recent News About These Companies

Three Biotechs That Are Top Takeover Targets
Lilly Doubles Down on Eye Diseases, Adding to BD Spree

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Gogo stock logo

Gogo NASDAQ:GOGO

$4.57 -0.21 (-4.39%)
Closing price 04:00 PM Eastern
Extended Trading
$4.56 -0.01 (-0.22%)
As of 04:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Gogo Inc., together with its subsidiaries, provides broadband connectivity services to the aviation industry in the United States and internationally. The company's product platform includes networks, antennas, and airborne equipment and software. It offers in-flight systems; in-flight services; aviation partner support; and engineering, design, and development services, as well as production operations functions. The company offers voice and data, in-flight entertainment, and other services. In addition, it engages in the development, deployment, and operation of networks, towers, and data center infrastructure to support in-flight connectivity services, as well as in the provision of telecommunications connections to the internet. The company sells its products primarily to aircraft operators and original equipment manufacturers of business aviation aircraft through a distribution network of independent dealers. Gogo Inc. was founded in 1991 and is headquartered in Broomfield, Colorado. As of May 2024, Gogo Inc. claims that "Gogo is the only company in North America with a complete, certified airborne 5G network, meaning that all components within the network (including onboard equipment) are 5G native."

Kohl's stock logo

Kohl's NYSE:KSS

$14.41 -1.18 (-7.58%)
Closing price 03:59 PM Eastern
Extended Trading
$14.34 -0.07 (-0.47%)
As of 04:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Kohl's Corporation operates as an omnichannel retailer in the United States. It offers branded apparel, footwear, accessories, beauty, and home products through its stores and website. The company provides its products primarily under the brand names of Croft & Barrow, Jumping Beans, SO, Sonoma Goods for Life, and Tek Gear, as well as Food Network, LC Lauren Conrad, Nine West, and Simply Vera Vera Wang. Kohl's Corporation was founded in 1988 and is headquartered in Menomonee Falls, Wisconsin.

Kohl's stock logo

Kohl's NYSE:KSS

$14.41 -1.18 (-7.58%)
Closing price 03:59 PM Eastern
Extended Trading
$14.34 -0.07 (-0.47%)
As of 04:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Kohl's Corporation operates as an omnichannel retailer in the United States. It offers branded apparel, footwear, accessories, beauty, and home products through its stores and website. The company provides its products primarily under the brand names of Croft & Barrow, Jumping Beans, SO, Sonoma Goods for Life, and Tek Gear, as well as Food Network, LC Lauren Conrad, Nine West, and Simply Vera Vera Wang. Kohl's Corporation was founded in 1988 and is headquartered in Menomonee Falls, Wisconsin.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,105.37 -21.43 (-1.90%)
Closing price 03:59 PM Eastern
Extended Trading
$1,100.10 -5.27 (-0.48%)
As of 04:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Intellia Therapeutics stock logo

Intellia Therapeutics NASDAQ:NTLA

$14.07 +0.39 (+2.85%)
Closing price 04:00 PM Eastern
Extended Trading
$13.98 -0.09 (-0.60%)
As of 04:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Verve Therapeutics stock logo

Verve Therapeutics NASDAQ:VERV

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.